Inactivated dengue virus vaccine
First Claim
Patent Images
1. A vaccine comprising a purified, inactivated dengue virus effective for inducing a protective immune response in primates against dengue virus.
1 Assignment
0 Petitions
Accused Products
Abstract
An inactivated dengue virus vaccine to immunize and protect humans against dengue fever is described. The vaccine is based on dengue viruses which have been propagated to high titers in suitable cells, purified and inactivated under conditions which destroy infectivity but preserve immunogenicity, a high level of which is demonstrated in animal models.
12 Citations
28 Claims
- 1. A vaccine comprising a purified, inactivated dengue virus effective for inducing a protective immune response in primates against dengue virus.
-
16. A dengue 2 virus vaccine produced by inactivating a dengue 2 virus deposited at ATCC under accession no. VR2650.
-
17. A multivalent vaccine comprising purified inactivated dengue virus propagated in vertebrate tissue culture cells and effective for inducing a protective immune response in primates against dengue virus wherein said virus is chosen from the group consisting of purified inactivated dengue virus type 1, purified inactivated dengue virus type 2, purified inactivated dengue virus type 3, and purified inactivated dengue virus type 4.
- 18. An isolated dengue type 1 virus having ATCC accession number VR-2649.
- 21. An isolated dengue type 2 virus having ATCC accession number VR-2650.
- 23. An isolated dengue type 3 virus having ATCC accession number VR-2654.
- 26. An isolated dengue type 4 virus having ATCC accession number VR-2651.
Specification